KYTX · Insider Trading
Kyverna Therapeutics, Inc. Common Stock
Every open-market purchase and sale reported by KYTX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-29 | Ian T Clark | Director | A | +5,093 | — |
| 2026-05-29 | Beth C Seidenberg | Director | A | +5,093 | — |
| 2026-05-29 | Christi Shaw | Executive Chairperson | F | −4,194 | −$36.03K |
| 2026-05-29 | Mert Aktar | Director | A | +5,093 | — |
| 2026-05-29 | Fred E Cohen | Director | A | +5,093 | — |
| 2026-05-20 | Gregory S. Martini | Chief Financial Officer | A | +325,000 deriv. | — |
| 2026-05-06 | Nadia Dac | Chief Commercial Officer | A | +300,000 deriv. | — |
| 2026-03-17 | Warner Weston Biddle | Chief Executive Officer | A | +58,000 | — |
| 2026-03-17 | Marc Grasso | Chief Financial Officer | A | +10,000 | — |
| 2026-03-17 | Naji Gehchan | See Remarks | A | +18,000 | — |
| 2026-03-04 | Andrew Craig Miller | Director | A | +11,006 | — |
| 2026-02-26 | Sravan Kumar Emany | Director | A | +11,006 | — |
| 2026-02-11 | Mayobanex Pujols | Chief Technology Officer | A | +300,000 deriv. | — |
| 2026-01-14 | Christi Shaw | Executive Chairperson | A | +54,301 | — |
| 2025-12-22 | Westlake BioPartners GP I, LLC | 10%+ Owner | Buy | +533,332 | +$4.00M |
| 2025-12-22 | Beth C Seidenberg | Director | Buy | +133,333 | +$1000.00K |
| 2025-12-17 | Karen Marie Walker | Chief Technology Officer | MIXED | — | −$176.87K |
| 2025-07-01 | Marc Grasso | Chief Financial Officer | A | −450,000 deriv. | — |
| 2025-06-02 | Daniel K Spiegelman | Director | A | +16,634 | — |
| 2025-06-02 | Ian T Clark | Director | A | +16,634 | — |
| 2025-06-02 | Beth C Seidenberg | Director | A | +16,634 | — |
| 2025-06-02 | Fred E Cohen | Director | A | +16,634 | — |
| 2025-06-02 | Mert Aktar | Director | A | +16,634 | — |
| 2025-06-02 | Christi Shaw | Director | A | +16,634 | — |
| 2025-04-15 | Warner Weston Biddle | Chief Executive Officer | A | +332,500 deriv. | — |
| 2025-04-15 | Ryan Alexander Jones | Chief Financial Officer | A | +12,000 | — |
| 2025-04-15 | Karen Marie Walker | Chief Technology Officer | A | +13,000 | — |
| 2025-02-19 | Christi Shaw | Director | A | +38,679 deriv. | — |
| 2025-01-24 | Naji Gehchan | See Remarks | A | +425,000 deriv. | — |
| 2024-10-24 | Mert Aktar | Director | A | +87,741 deriv. | — |
| 2024-09-18 | Warner Weston Biddle | Chief Executive Officer | A | +2,579,259 deriv. | — |
| 2024-09-18 | Christi Shaw | Director | A | +66,592 deriv. | — |
| 2024-06-10 | Karen Marie Walker | Chief Technology Officer | M | +9,636 | +$42.59K |
| 2024-05-29 | Ryan Alexander Jones | Chief Financial Officer | M | +18,016 | +$13.15K |
| 2024-02-14 | Fred E Cohen | Director | C | +4,523,924 | — |
| 2024-02-14 | Bain Capital Life Sciences Fund III, L.P. | 10%+ Owner | MIXED | +15,819,340 | +$49.50M |
| 2024-02-14 | Beth C Seidenberg | Director | C | +4,523,924 | — |
| 2024-02-14 | Vida Ventures GP III, L.L.C. | 10%+ Owner | MIXED | +19,108,240 | +$22.28M |
| 2024-02-14 | Westlake BioPartners Opportunity GP I, LLC | 10%+ Owner | C | +22,619,620 | — |
| 2024-02-13 | GILEAD SCIENCES, INC. | 10%+ Owner | MIXED | +4,126,119 | +$20.02M |
| 2024-02-12 | Michael P. Rubin | — | MIXED | +9,766,278 | +$29.70M |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Fred E Cohen | Director | 4,545,651 | $23.96M |
| Beth C Seidenberg | Director | 3,809,667 | $20.08M |
| Westlake BioPartners GP I, LLC | 10%+ Owner | 3,787,940 | $19.96M |
| Christi Shaw | Executive Chairperson | 66,741 | $351.73K |
| Warner Weston Biddle | Chief Executive Officer | 58,000 | $305.66K |
| Ryan Alexander Jones | Chief Financial Officer | 55,950 | $294.86K |
| Karen Marie Walker | Chief Technology Officer | 46,634 | $245.76K |
| Ian T Clark | Director | 21,727 | $114.50K |
| Mert Aktar | Director | 21,727 | $114.50K |
| Naji Gehchan | See Remarks | 18,000 | $94.86K |
| Daniel K Spiegelman | Director | 16,634 | $87.66K |
| Andrew Craig Miller | Director | 11,006 | $58.00K |
| Sravan Kumar Emany | Director | 11,006 | $58.00K |
| Marc Grasso | Chief Financial Officer | 10,000 | $52.70K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the KYTX quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.